

Date: May 15, 2026

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Sub.: Newspaper Publication – Extracts of Audited Financial Results of the Company for quarter and financial year ended March 31, 2026

Dear Sir/Madam,

Pursuant to Regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copies of Newspaper Publications of the extracts of Audited Consolidated and Standalone Financial Results of the Company for quarter and financial year ended March 31, 2026, as published, in Financial Express -English and Gujarati Edition, on May 15, 2026.

This intimation is also being uploaded on the website of the Company i.e. www.senorespharma.com.

You are requested to take the same on record.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Enclosures: As above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

JTPM METAL TRADERS LIMITED

Registered Office: JSW Centre, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. CIN: U46620MH2017PLC0405988

EXTRACT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & FINANCIAL YEAR ENDED MARCH 31, 2026 AND AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2026

Sr. No.	Particulars	Standalone						Consolidated	
		Quarter Ended			Year Ended			Year Ended	
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025	31.03.2026	31.03.2025	
1	Total Income from Operations	7,978.25	86.77	953.65	13,304.42	16,020.45	14,010.84	16,020.45	
2	Net Profit / (Loss) for the period/ year (before Tax, Exceptional and/or Extraordinary items)	(3,899.21)	2,567.21	(3,366.62)	(7,144.24)	(5,493.96)	(12,522.14)	(5,493.96)	
3	Net Profit / (Loss) for the period/ year before tax (after Exceptional and/or Extraordinary items)	(3,899.21)	2,567.21	(3,366.62)	(7,144.24)	(5,493.96)	(12,522.14)	(5,493.96)	
4	Net Profit / (Loss) for the period/ year after tax (after Exceptional and/or Extraordinary items)	(5,011.73)	4,605.67	(4,075.66)	(6,683.10)	(6,426.02)	(10,574.09)	(6,426.02)	
5	Total Comprehensive Income/ (Loss) for the period / year (after tax) and other comprehensive income (after tax)	(84,297.77)	35,901.86	130,691.26	(27,608.53)	218,599.55	32,808.05	218,599.55	
6	Paid up Equity Share Capital	131,703.00	131,703.00	121,502.00	131,703.00	121,502.00	131,703.00	121,502.00	
7	Reserves (excluding Revaluation Reserves)	505,429.79	589,730.10	504,682.08	505,429.79	504,682.08	565,846.37	504,682.08	
8	Securities Premium Account	28,358.78	28,358.78	-	28,358.78	-	28,358.78	-	
9	Net worth	637,132.79	721,433.10	664,743.86	637,132.79	664,743.86	697,549.37	664,743.86	
10	Paid up Debt Capital / Outstanding Debt	864,557.31	876,804.16	279,962.93	864,557.31	279,962.93	864,557.31	279,962.93	
11	Outstanding Redeemable Preference Shares	-	-	-	-	-	-	-	
12	Debt Equity Ratio	1.36	1.22	0.42	1.36	0.42	1.24	0.42	
13	Earnings per share (of ₹10 each)								
	Basic (₹)	(0.04)	0.03	(0.03)	(0.51)	(0.49)	(0.81)	(0.49)	
	Diluted (₹)	(0.04)	0.03	(0.03)	(0.51)	(0.49)	(0.81)	(0.49)	
14	Capital Redemption Reserve	-	-	-	-	-	-	-	
15	Debt Redemption Reserve	-	-	-	-	-	-	-	
16	Debt Service Coverage Ratio	(0.00)	(0.00)	(0.00)	0.07	0.15	0.07	0.15	
17	Interest Service Coverage Ratio	(0.00)	(0.00)	(0.15)	0.07	1.04	0.07	1.04	

*The Company was not required to prepare consolidated financial statements for financial year ended 31st March 2025.

Notes:

- The above is an extract of the detailed format of Standalone Audited financial result for the quarter and year ended March 31, 2026 and Consolidated Audited financial result for the year ended March 31, 2026 filed with the Stock Exchanges, BSE Limited, under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations). The detailed information on the financial results including details required under the Regulation 52 (4) of SEBI LODR Regulations is available on the websites of the Stock Exchange at www.bseindia.com.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 13, 2026. The statutory auditors have carried out an audit of the results for the quarter and financial year ended March 31, 2026.
- The above results are in accordance with the companies (Indian Accounting Standards) Rules 2015 (Ind AS) prescribed under Section 133 of Companies Act 2013 read with relevant rules issued thereunder and other Accounting Principles Generally accepted in India.
- For the other line items referred in Regulations 52(4) SEBI (Listing and Other Disclosure Requirements) Regulation 2015, pertinent disclosures have been made to the stock exchanges website of the Stock Exchange at www.bseindia.com.

Place: Mumbai
Date: May 13, 2026

Sd/-
Badri Narain Singh
Director
DIN: 06794208

CAPLIN POINT LABORATORIES LIMITED

CIN - L24231TN1990PLC019053

Registered office : 3rd Floor, "Asthvich Towers", No.3, Developed Plots Industrial Estates, Perungudi, Chennai 600 096.
Phone No.044-2496 8000. Website - www.caplinpoint.net, email ID - info@caplinpoint.net

EXTRACT OF STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH 2026 PREPARED IN COMPLIANCE WITH INDIAN ACCOUNTING STANDARDS

Sl. No.	Particulars	Consolidated				
		Quarter ended			Year ended	
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
1	Total Income	628.52	576.45	528.19	2,302.73	2,033.90
2	Net Profit / (Loss) for the period before share of profit in Associate, Tax, Exceptional and / or Extraordinary items	213.44	203.91	176.59	802.75	676.79
3	Net Profit / (Loss) for the period before tax (after share of profit in Associate, Exceptional and / or Extraordinary items)	213.44	203.89	176.67	802.79	676.78
4	Net Profit / (Loss) for the period after tax (after share of profit in Associate, Exceptional and / or Extraordinary items)	172.88	165.86	145.28	649.73	541.09
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	249.78	182.70	143.53	791.37	568.16
6	Equity Share Capital	15.20	15.20	15.20	15.20	15.20
7	Other Equity (excluding Non Controlling Interest) as shown in the Audited Balance Sheet	-	-	-	3,571.22	2,835.29
8	Earnings Per Share (of ₹ 2/- each) (for continuing and discontinued operations)					
	1. Basic: (in ₹)	22.38	21.56	18.75	84.36	70.57
	2. Diluted: (in ₹)	22.31	21.51	18.69	84.11	70.25
		(Not Annualised)			(Annualised)	

Note:

1. Key numbers of Standalone Results are as under:

Particulars	Consolidated				
	Quarter ended			Year ended	
	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
Total Income	252.44	220.95	214.86	933.70	887.00
Profit Before Tax	137.72	117.01	110.16	507.52	441.67
Profit After Tax	109.50	87.28	86.50	396.58	339.49

- The above is an extract of the detailed format of the Quarter and Year ended 31st March 2026 Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the website of stock exchanges viz., BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and on the Company's website (www.caplinpoint.net).
- The audited financial results for the Quarter and Year ended 31st March 2026 have been recommended by the Audit Committee of the Board and approved by the Board of Directors of the Company at their respective meetings held on 14th May, 2026.

Place : Chennai
Date : 14th May, 2026

For Caplin Point Laboratories Limited
Dr Sridhar Ganesan
Managing Director
DIN 06819026

NATIONAL HIGHWAYS INFRA TRUST

Regd. Office: NHAI Corporate Office,
Plot No.G-5 and 6, Sector 10, Dwarka, New Delhi - 110075, India

Registration Number (Infrastructure Investment Trusts Regulations, 2014) : IN/InvIT/20-21/0014

STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

Sl. No.	Particulars	Standalone						Consolidated					
		Quarter ended			Year ended			Quarter ended			Year ended		
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025		
1	Total income from operations	124,023.51	126,356.80	77,753.67	504,566.13	305,953.98	115,990.02	111,655.28	66,446.39	4,32,220.76	241,558.30		
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	102,082.29	84,963.95	33,300.84	353,897.97	186,639.33	10,686.36	15,496.39	8,570.53	31,994.74	12,232.70		
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	102,082.29	84,963.95	33,300.84	353,897.97	186,639.33	10,686.36	15,496.39	8,570.53	31,994.74	12,232.70		
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	101,913.14	84,787.07	32,972.22	353,114.51	185,491.35	20,455.44	24,741.05	14,050.71	68,551.88	32,500.62		
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	101,913.14	84,787.07	32,972.22	353,114.51	185,491.35	20,479.25	24,741.02	14,054.66	68,575.92	32,500.00		
6	Paid up Unit Capital	2,600,167.93	2,292,715.44	2,297,095.67	2,600,167.93	2,297,095.67	2,600,167.93	2,292,715.44	2,297,095.67	2,600,167.93	2,297,095.67		
7	Initial Settlement Amount	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10		
8	Other Equity (excluding Revaluation Reserve)	347,719.35	321,420.66	183,525.25	347,719.35	183,525.25	(220,112.66)	(164,977.29)	(99,768.17)	(220,112.66)	(99,768.17)		
9	Securities Premium	-	-	-	-	-	-	-	-	-	-		
10	Net Worth	2,947,887.38	2,614,136.40	2,480,621.02	2,947,887.38	2,480,621.02	2,380,055.37	2,127,738.25	2,197,327.60	2,380,055.37	2,197,327.60		
11	Paid up Debt Capital/Outstanding Debt	2,503,915.14	2,170,211.36	2,167,049.23	2,503,915.14	2,167,049.23	2,503,915.14	2,170,211.36	2,167,049.23	2,503,915.14	2,167,049.23		
12	Outstanding Redeemable Preference Unit Capital	-	-	-	-	-	-	-	-	-	-		
13	Debt Equity Ratio *	-	-	-	-	-	1.05	1.02	0.99	1.05	0.99		
14	Earnings Per Unit Capital												
	1. Basic:	5.25	4.38	2.41	18.20	13.99	1.06	1.28	1.03	3.53	2.45		
	2. Diluted:	5.25	4.38	2.41	18.20	13.99	1.06	1.28	1.03	3.53	2.45		
15	Capital Redemption Reserve	-	-	-	-	-	-	-	-	-	-		
16	Debt Redemption Reserve	-	-	-	-	-	-	-	-	-	-		
17	Debt Service Coverage Ratio *	-	-	-	-	-	2.80	2.05	2.34	2.26	2.10		
18	Interest Service Coverage Ratio *	-	-	-	-	-	3.22	2.30	2.63	2.56	2.33		

Note: * All ratios are reported at Consolidated Level.

- The above Standalone and Consolidated financial results of National Highways Infra Trust for the Quarter and Year ended March 31, 2026 are approved by the Board on May 13, 2026.
- The above is an extract of the detailed format of Standalone and Consolidated Financial results for the quarter and year ended March 31, 2026 filed with the Stock Exchanges under SEBI (Infrastructure Investment Trust) Regulations, 2014 (InvIT regulations) and circulars issued thereunder read with regulation 52 of the SEBI LODR Regulations, 2015. The full format of the Standalone and Consolidated financial results for the quarter and year ended March 31, 2026 is available on the website of Stock Exchanges (www.nseindia.com and www.bseindia.com) and the website of the Trust (www.nhit.co.in).

For and on behalf of the National Highways Infra Trust
-sd-
Rakshit Jain
Managing Director & CEO
National Highways Infra Investment Managers Private Limited
(Investment Manager of National Highways Infra Trust)

Place: New Delhi
Date: 13th May 2026



SENORES PHARMACEUTICALS LIMITED

(Formerly known as Senores Pharmaceuticals Private Limited)

Corporate Identification Number: L24290GJ2017PLC100263

Registered Office: 1101 to 1103, 11th Floor, South Tower, One 42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad - 380054, Gujarat, India
Website: www.senorespharma.com | E-mail ID: cs@senorespharma.com | Telephone: +91-79-29999857

EXTRACT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND FINANCIAL YEAR ENDED MARCH 31, 2026

(Pursuant to regulation 33 read with regulation 47(1) (b) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015)
(₹ in crore except for per share data)

Sr. No.	Particulars	STANDALONE					CONSOLIDATED				
		Quarter Ended		Year Ended			Quarter Ended		Year Ended		
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025	31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025
1	Total Income from Operations (Net)	59.00	38.54	21.11	172.44	60.53	192.86	178.34	125.98	679.69	417.51
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items)	12.69	3.52	2.90	27.46	5.11	47.40	44.60	20.68	159.10	70.57
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or extraordinary items)	12.69	3.52	2.90	27.46	5.11	47.40	44.60	20.68	159.10	70.57
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or extraordinary items)	8.48	2.65	2.02	20.25	3.69	36.67	33.58	17.97	121.53	58.34
5	Total Comprehensive Income/(Loss) for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	8.54	2.68	1.82	20.24	3.46	78.59	28.79	17.85	150.72	54.82
6	Paid-up Equity Share Capital	-	-	-	46.05	46.05	-	-	-	46.05	46.05
7	Reserves (excluding Revaluation Reserve)	-	-	-	703.85	661.91	-	-	-	887.55	740.13
8	Earning Per Share (of Rs. 10/-each)										
	1. Basic:	1.84	1.98	0.39	4.40	1.02	7.96	7.29	3.81	26.39	16.12
	2. Diluted:	1.84	1.98	0.39	4.40	1.02	7.96	7.29	3.81	26.39	16.12

Notes:

- EPS for the respective periods have been calculated based on the weighted average number of shares outstanding for the said periods.
- The above is an extract of the detailed format of Audited Financial Results filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Audited Financial Results are available on the websites of the Stock Exchange viz. www.bseindia.com and www.nseindia.com and on Company's website viz. www.senorespharma.com and can be accessed by scanning the Quick Response Code ("QR Code") below.



Scan the QR Code to view the detailed Results on the website of the Company

By Order of the Board of Directors
For Senores Pharmaceuticals Limited
Sd/-
Swapnil Shah (Managing Director)
DIN: 05259821

Date: May 14, 2026
Place: Ahmedabad

ICICI Lombard

IC

